Relebactam

Relebactam
Clinical data
Other names	MK-7655
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name [(2S,5R)-7-Oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate;
CAS Number	1174018-99-5;
PubChem CID	44129647;
DrugBank	DB12377;
ChemSpider	31137585;
UNII	1OQF7TT3PF;
Chemical and physical data
Formula	C12H20N4O6S
Molar mass	348.37 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3;
	InChI InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1; Key:SMOBCLHAZXOKDQ-ZJUUUORDSA-N;

Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor,[1] it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).[2]

References

Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. (June 2018). "Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae". Antimicrobial Agents and Chemotherapy. 62 (6). doi:10.1128/AAC.00174-18. PMC 5971601. PMID 29610205.
"FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, et al. (June 2018). "Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae". Antimicrobial Agents and Chemotherapy. 62 (6). doi:10.1128/AAC.00174-18. PMC 5971601. PMID 29610205.

[2] "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, 2019.

Relebactam

See also

References